Welcome to our dedicated page for Haleon news (Ticker: HLN), a resource for investors and traders seeking the latest updates and insights on Haleon stock.
Haleon plc reports consumer health developments across Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health and Other. The company's news commonly covers product launches and brand activity for names such as Sensodyne, parodontax, Centrum, Advil, TUMS, Theraflu, Voltaren, Polident and Panadol.
Recurring updates include oral-care innovation, multivitamin research, consumer marketing campaigns, regional growth initiatives, manufacturing investment, and leadership changes within the U.S. and other markets. As a foreign issuer with American depositary shares traded under HLN, company announcements may also address parent-company reporting, governance and capital-market communications.
Centrum Silver (HLN) was evaluated in a COSMOS ancillary randomized trial analysis showing a small but measurable slowing of DNA-based biological aging over two years. The multivitamin group exhibited slowing across five epigenetic clocks, with about four months less biological aging versus placebo and statistical significance in two mortality‑predictive clocks.
Nearly 1,000 older adults were randomized and followed for two years; authors say effects were larger for participants with accelerated baseline biological age and that further research is needed to link clock changes to long‑term health outcomes.
Sensodyne (HLN) launched Sensodyne Clinical Repair on February 10, 2026, a toothpaste claiming to start repairing sensitive areas after 60 seconds and deliver clinically proven, long‑lasting relief with twice‑daily brushing. The formula forms a protective layer that restrengthens with continued use and showed harder, more complete coverage versus two leading competitors. Available in Whiten & Shine and Fresh Clean, the product is sold now at major retailers with an MSRP of $8.99.
TUMS (HLN) launched a game-day promotion on Jan 6, 2026: a limited-edition Burn Ball (a football-shaped TUMS case) sold exclusively on TUMSshop.com and a social sweepstakes with creator Airrack to promote trick-pass videos and heartburn relief.
The #PassTheTUMSSweepstakes runs Jan 9–25, 2026, with a $5,000 grand prize and 50 additional $50 UberEats cards; entry via Instagram, TikTok, or YouTube Shorts. The Burn Ball opens to reveal a bottle of TUMS Chewy Bites. Campaign emphasizes fast-acting relief and ties to TUMS product formats.
Glasgow Caledonian University (HLN) will lead a £2.6m, six-year UK doctoral training programme to advance research in oral health and dental disease prevention.
The initiative will support 20 PhD students across five universities, focusing on dental caries prevention, dentine hypersensitivity and gum health, and is funded by BBSRC in partnership with industry partner Haleon. The award is part of a wider £40m package of Industrial Doctoral Landscape Awards and Doctoral Focal Awards announced by UKRI/BBSRC on 16 December 2025.
Haleon (HLN) was honored on December 12, 2025 as a 2025 Fast Company Brands That Matter honoree in the Family of Brands category. The recognition highlights Haleon’s portfolio-level impact, citing cultural relevance, meaningful consumer connection, and purpose-driven innovation across brands such as Sensodyne, Centrum, Advil, Voltaren, Emergen-C, and Theraflu. The company emphasized science-backed products, transparent communication, cross-brand collaboration, and consumer education as drivers of trust and emotional resonance. The award underscores Haleon’s stated mission to expand everyday health access by uniting diverse brands under a shared purpose.
Altibbi partnered with Haleon (HLN) on the Healthy Saudi Smile campaign, announced Nov 24, 2025, to turn oral-health awareness into actionable care across Saudi Arabia.
Altibbi provided Arabic-language, science-based education and connected users to certified doctors for instant consultations, supporting strong engagement and enabling thousands to receive trusted oral-health guidance. The campaign links brand purpose, local expertise, and digital access and aligns with preventive-health priorities in Saudi Vision 2030.
Altibbi plans to expand similar collaborations with health and wellness brands to combine education, access, and care.
Haleon (LSE/NYSE:HLN) announced on October 8, 2025 it selected Salesforce Life Sciences Cloud for Customer Engagement, Data Cloud, and Agentforce to support its global sales organisation. The AI-powered rollout will cover Haleon's 4,500-strong sales force to improve engagement with pharmacies and healthcare professionals and to deliver data-driven insights on consumer demographics, shopping trends, and point-of-sale marketing.
Haleon will serve as a design partner to influence product availability, shelf-life management, promotions, and inventory features for consumer health use cases. The company said the change aims to reduce administrative time for reps and enable more bespoke activation plans for customers worldwide.
Aptar Pharma (NYSE:ATR) has announced a significant sustainability milestone with its Freepod® nasal spray pump, used in Haleon's Otrivin® brand, now being manufactured with 52% bio-based feedstock. This marks the first Aptar delivery system using such materials to be commercialized globally.
The innovative solution features an ISCC Plus certified manufacturing process, with the bottle produced using a mass balance approach equivalent to 100% bio-based content. Combined, the pump and bottle components achieve 60% circular material content for the complete nasal spray device. The manufacturing site in Mezzovico, Switzerland, maintains ISCC PLUS certification, ensuring complete material traceability.
This development supports Haleon's sustainability goals of reducing virgin petroleum-based plastic use by 10% by 2025 and by a third by 2030, compared to 2022 levels.
Haleon (NYSE:HLN) has initiated construction of its new £130 million Global Oral Health Innovation Centre in Weybridge, Surrey. The groundbreaking ceremony was attended by UK Minister Baroness Jones and marks a significant step in Haleon's mission to reach one billion more consumers by 2030.
The state-of-the-art facility will serve as the R&D epicenter for Haleon's oral health portfolio, featuring a digital immersive room for real-time collaboration with its Levice manufacturing site. The center has achieved a BREEAM® Outstanding rating for its sustainability design and will focus on developing solutions for unmet oral health needs globally.
Haleon (NYSE: HLN) has appointed Carl Haney as Chief Research & Development Officer, effective August 1, 2025. Haney joins from Estée Lauder Companies Inc., where he served as Executive Vice President of Global Innovation and R&D for 13 years, following a 20-year tenure at P&G.
Haney succeeds Franck Riot, who is departing after six years with the company. CEO Brian McNamara highlighted Haney's expertise in driving transformative innovation within global consumer businesses, emphasizing his role in implementing Haleon's new Win as One strategy.